Drug Prices

Trump announces lower drug price deals with 9 major pharma companies

US President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the US. Pharmaceutical companies Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi will now rein in Medicaid drug prices to match what they charged in other developed countries. As part of the deal, new drugs made by those companies will also be charged at the so-called most-favoured-nation pricing across the country on any newly launched medications for all, including commercial and cash pay markets as well as Medicare and Medicaid. Drug prices for patients in the US can depend on a number of factors, including the competition a treatment faces and insurance coverage. Most people have coverage through work, the individual insurance market or government programs like Medicaid and Medicare, which shield them from much of the cost. Patients in Medicaid, the state and federally funded program for peopl

Price cuts drove market gains in November for Novo Nordisk's Wegovy

Novo Nordisk cut Wegovy prices in mid-November, driving a 70% consumption jump and higher market share. Pharmarack data show Lilly's Mounjaro still dominates sales

Pfizer's drug-price deal with Trump follows months of negotiation deadlock

Pfizer and the White House were deadlocked for months over lowering US drug prices, with Trump demanding quick results from drug executives right from the start of his second term

Trump's plans to cut drug prices in US may impact Indian pharma landscape

Trump's executive order, dated May 12, seeks to establish a mechanism through which American patients can buy their drugs directly from the manufacturers

Delhi Cabinet approves three health reforms, including OPD outsourcing

The Delhi Cabinet on Tuesday gave its nod to three major health sector reforms aimed at improving service delivery and infrastructure in government hospitals, including the setting up of a price monitoring and resource unit, and the outsourcing of OPD/IPD registrations and diagnostic services. Delhi Health Minister Pankaj Singh told PTI that the government, in its efforts to enhance health infrastructure, approved three key reforms on Tuedday. He said that the three agenda items -- centred on price regulation, operational outsourcing, and PPP-driven diagnostic services -- reflect the government's focus on strengthening healthcare delivery and governance in the capital. Every day, the Delhi government is taking steps to provide the best facilities in our hospitals, Singh said.

Cardiac stents to cost 2% more as regulator allows prices to be raised

National Pharmaceutical Pricing Authority allows manufacturers to make adjustment for inflation

NPPA under fire for 50% rise in drug prices, panel demands explanation

Parliamentary panel slams drug pricing regulator for hike on 11 drugs used for treating conditions such as asthma, glaucoma, thalassemia, tuberculosis, and mental health disorders

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

The ceiling prices of seven other drugs were revised to include the impact of the 0.00551 per cent increase in drug prices in the National List of Essential Medicines

Imports of bulk drugs grew by 13.06% in April-May as prices cooled

Industry insiders say pharma players are taking advantage and stocking up on APIs

Indian pharmaceutical companies likely to cash in on US drug shortages

US drug shortages hit a decade-high of 323 across 22 therapies in the March quarter of 2024

Panel formed to administer pricing reforms for drugs, medical devices

Centre constitutes Committee for reforms in pricing framework for drugs and medical devices

Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

Power crisis brewing in China likely to hit Indian pharma companies

Delays in consignments, rising prices of key ingredients worry industry

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

These are scheduled drugs (or ones that are under price control) and low priced

Donald Trump signs new, expanded executive order to lower US drug prices

Donald Trump signed a new executive order on Sunday aimed at lowering drug prices in the United States by linking them to those of other nations and expanding the scope of a July action

Drug price monitoring unit set up in Karnataka under aegis of NPPA

The government on Thursday said aprice monitoring and resource unit (PMRU) has been set up in Karnataka under the aegis of the National Pharmaceutical Pricing Authority (NPPA)

More drugs may see price revisions as raw material costs, expenses rise

API prices have gone up by 25-30 per cent for some drugs in recent months

Remdesivir pricing in India likely to be lower than global rate: Sources

Indian companies await clarity from the drug regulator on animal toxicology study before they can launch here

A lesson to learn: Economic problems can have counter-intuitive solutions

From drug price ceiling to additional duties on steel imports and export ban to counter onion shortage - govt response to several problems shows the lessons may not have been learnt, writes T N Ninan

Novartis, Merck, Allergan raise US prices, 445 drugs to cost more in 2020

That is above the average of 404 drug price increases in the first three days of January over the past five years